Breaking News, Collaborations & Alliances

Lunai Bioworks Acquires $20M in BBB Delivery Tech, CNS Alzheimer’s Assets from Clemann Group

The acquisition gives Lunai a delivery platform addressing a critical bottleneck in CNS drug development.

Author Image

By: Patrick Lavery

Content Marketing Editor

Lunai Bioworks is announcing a binding, $20 million strategic transaction acquiring drug delivery technology and assets from the Clemann Group. Lunai describes itself as an AI-driven life sciences company; Clemann Group supports activities from discovery to clinical and marketization activities. Details on Acquisition from Clemann The acquisition consists of blood-brain barrier (BBB) delivery technology and central nervous system (CNS) Alzheimer’s disease drug assets. It is a Series B Conv...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters